Houng Kim

发表

The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?

G. Heap, Tariq Ahmad, S. Ben-Horin, 2015, Expert review of gastroenterology & hepatology.

Sang Joon Lee, Michael Tee, Pedro Miranda, 2013 .

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study

P. Miranda, W. Park, A. Baranauskaitė, 2016, Annals of the rheumatic diseases.

Biosimilars for the management of rheumatoid arthritis: economic considerations

S. Y. Kim, M. Péntek, P. Baji, 2015, Expert review of clinical immunology.

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study

P. Miranda, J. Braun, W. Park, 2016, Annals of the rheumatic diseases.

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Sergio Gutierrez-Ureña, HoUng Kim, Won Park, 2013, Annals of the rheumatic diseases.

Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer

S. Park, Jeeyun Lee, H. Lim, 2018, Cancer Chemotherapy and Pharmacology.

Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.

F. Esteva, J. Stebbing, T. Saeki, 2018, Future oncology.

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Edgar Ramiterre, Nenad Prodanovic, Mauricio Abello-Banfi, 2013, Annals of the rheumatic diseases.

Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

S. Fishman, B. Ye, Kang-Moon Lee, 2019, The Lancet.

Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer (MBC) as first-line treatment.

Sudeep Gupta, Y. Im, A. Makhson, 2013 .